PO.MCB07.01 · 分子与细胞生物学

基于超级增强子相关转录调控因子和生物标志物的患者来源三阴性乳腺癌模型分子特征

Molecular features of patient-derived triple-negative breast cancer models based on super-enhancer-associated transcriptional regulators and biomarkers

编号 4770 展板 20 时间 4/21 09:00–12:00 区域 Section 24 主讲 Kuniko Horie, MD;PhD
分会场 Oncogenic Transcription Factors and Cancer Programs
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Kuniko Horie1, Kazuhiro Ikeda1, Satoshi Inoue2

1Saitama Medical University, Saitama, Japan,2Professor, Dept. of Anti-Aging Med., TMIG - Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan

摘要 Abstract

中文摘要
超级增强子(SE)被定义为具有连续增强子簇的特定基因组区域,可提供细胞特异性或阶段特异性的背景。SE通常由转录共激活因子的高水平基因组结合富集以及活性染色质标记(如乙酰化K27的组蛋白H3)来确定。在本研究中,我们旨在表征从不同晚期病例获得的患者来源三阴性乳腺癌(TNBC)模型中SE相关基因谱的相似性和特异性。我们基于RNA测序和针对H3K27ac结合的染色质免疫沉淀(ChIP)测序的整合研究,识别了这些模型的SE相关基因。由于这些患者来源的癌症模型是通过球体培养技术生成的,干性标志物如CD44和MYC被识别为大多数病例中占主导地位的SE相关基因。我们进一步识别出MYBL1是基底样癌症病例中一个关键的SE相关转录因子。在TNBC患者来源模型和细胞系模型中沉默MYBL1表明,该转录因子参与细胞增殖和有丝分裂相关基因表达的调控。在我们的TNBC队列中对MYBL1进行免疫组化研究显示,MYBL1免疫反应性是TNBC患者潜在的不良预后因素。本研究结果提示,对SE相关转录调控因子和生物标志物的表征将有助于理解TNBC亚型的分子特征以及为晚期疾病开发替代性潜在治疗靶点。
查看英文原文 English abstract
Super-enhancers (SEs) have been defined as particular genomic regions with clusters of consecutive enhancers, which provide cell- or stage-specific context. SEs are often determined by high-level enrichment for genomic binding of transcriptional coactivators and active chromatin marks such as histone H3 with acetylated K27. In this study, we aim to characterize similarity and specificity of SE-associated gene profiles of patient-derived models of triple-negative breast cancer (TNBC) obtained from distinct advanced cases. We identified SE-associated genes for these models based on the integrated study of RNA-sequencing and chromatin immunoprecipitation (ChIP) sequencing for H3K27ac binding. Since these patient-derived cancer models were generated through a spheroid culture technique, stemness markers such as CD44 and MYC were identified as predominant SE-associated genes in the majority of cases. We further identified MYBL1 as a critical SE-associated transcription factor among basal-like cancer cases. Silencing of MYBL1 in TNBC patient-derived and cell line models showed that this transcription factor contributes to cell proliferation and the regulation of mitosis-associated gene expression. Immunohistochemical study for MYBL1 in our TNBC cohort showed that MYBL1 immunoreactivity is a potential poor prognostic factor for TNBC patients. The present findings suggest that the characterization of SE-associated transcriptional regulators and biomarkers will facilitate the understanding of molecular features of TNBC subtypes and the development of alternative potential therapeutic targets for the advanced disease.
利益披露 Disclosure
K. Horie, None.. K. Ikeda, None.

← 返回 AACR 2026 检索